Uncategorized
nasal spray medication for treatment-resistant depression

FDA approves new nasal spray for treatment-resistant depression

Share

On March 5, the FDA approved Spravato (esketamine) nasal spray, in conjunction with an oral antidepressant, for treatment-resistant depression, but it’s only available through a restricted distribution system.

Read more via U.S. Food and Drug Administration.

cheryl meeGet your free access to the exclusive newsletter of American Nurse Journal and gain insights for your nursing practice.

NurseLine Newsletter

  • Hidden

*By submitting your e-mail, you are opting in to receiving information from Healthcom Media and Affiliates. The details, including your email address/mobile number, may be used to keep you informed about future products and services.

Test Your Knowledge

What are the key elements to consider when creating a successful initial prompt for AI in nursing education?

Recent Posts